OpenEvidence
AI copilot for physicians that helps clinicians make better decisions at the point of care.
- Founded
- 2022
- Headquarters
- Miami, FL
- Latest Round
- Series D
- Est. Valuation
- ~$12,000M
Investment Thesis
OpenEvidence is the fastest-growing application for physicians in history — an AI-powered clinical decision support platform used by a quarter of all US doctors. The platform helps clinicians make better decisions at the point of care by synthesizing medical literature, clinical guidelines, and research data through an intelligent interface.
Founded in 2022 by entrepreneur Daniel Nadler, OpenEvidence initially raised capital quietly before exploding onto the scene with a $75M Series A led by Sequoia Capital in February 2025 at a $1B valuation. The company announced a landmark content partnership with The New England Journal of Medicine and has since raised additional rounds at rapidly escalating valuations, reaching $12B by January 2026 with nearly $700M in total funding.
Physicians make life-or-death decisions based on medical knowledge that doubles every 73 days, but have no reliable way to stay current across 30M+ research papers, clinical guidelines, and drug interactions.
OpenEvidence is an AI copilot trained specifically on peer-reviewed medical literature that gives physicians instant, citation-backed answers to complex clinical questions — not generic chatbot responses, but evidence-graded recommendations.
Over 200,000 physicians have adopted the platform, making it one of the fastest-growing clinical AI tools, with usage concentrated among specialists facing the most complex diagnostic and treatment decisions.
Foundation models finally handle medical reasoning with enough accuracy for clinical use, and the explosion of new research (especially in oncology and rare diseases) has made human-only literature review physically impossible.